Novel extracellular matrix biomarkers as predictors of adverse outcome in chronic heart failure: association between biglycan and response to statin therapy in the CORONA trial.

@article{Ueland2015NovelEM,
  title={Novel extracellular matrix biomarkers as predictors of adverse outcome in chronic heart failure: association between biglycan and response to statin therapy in the CORONA trial.},
  author={Thor Ueland and P{\aa}l Aukrust and St{\aa}le Haugset Nymo and John Kjekshus Kjekshus and John J V McMurray and John Wikstrand and Dirk Block and Christian P. Zaugg and Lars Gullestad},
  journal={Journal of cardiac failure},
  year={2015},
  volume={21 2},
  pages={
          153-9
        }
}
BACKGROUND The extracellular matrix (ECM) plays an important role in left ventricular remodeling and progression of heart failure (HF). Biglycan and mimecan are ECM proteins that are abundantly expressed in cardiac tissue but have not been evaluated as prognostic markers in HF. We investigated their interaction with statin treatment and association with adverse outcome in chronic HF. METHODS AND RESULTS The association between serum levels of biglycan and mimecan and the primary end point… CONTINUE READING
BETA

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 22 REFERENCES